Literature DB >> 8909232

Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer.

T Ueda1, T Ichikawa, J Tamaru, A Mikata, K Akakura, S Akimoto, T Imai, O Yoshie, T Shiraishi, R Yatani, H Ito, J Shimazaki.   

Abstract

The KAI1 gene, recently identified as a metastatic suppressor gene for prostate cancer, was cloned and was revealed to be identical to the C33/IA4/ R2/4R9 gene. The expression of KAI1 protein was examined immunohistochemically in the tissues from 14 cases of benign prostatic hyperplasia and 46 cases of prostate cancer using mouse monoclonal anti-human C33 antibody. In benign prostatic hyperplasia tissues, KAI1 protein was uniformly expressed in the glandular cell membrane at cell-to-cell borders. The KAI1 protein in the tissues of untreated prostate cancer was also located at similar sites to those of benign prostatic hyperplasia, but the percentage of strongly positive cancer cells was correlated inversely to the Gleason pattern (P < 0.0001, one-way analysis of variance). There was also a statistically inverse correlation between the percentage of KAI1-positive cancer cells and the clinical stage (chi 2 = 9.6; P = 0.0081). In 4 cancer death cases relapsed from endocrine therapy, KAI1 protein was not stained in either primary or metastatic foci. These results indicate that the expression of KAI1 protein correlates to tumor characteristics in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8909232      PMCID: PMC1865252     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  32 in total

1.  Molecular cloning and characterization of an antigen associated with early stages of melanoma tumor progression.

Authors:  H Hotta; A H Ross; K Huebner; M Isobe; S Wendeborn; M V Chao; R P Ricciardi; Y Tsujimoto; C M Croce; H Koprowski
Journal:  Cancer Res       Date:  1988-06-01       Impact factor: 12.701

2.  Molecular cloning of the CD9 antigen. A new family of cell surface proteins.

Authors:  C Boucheix; P Benoit; P Frachet; M Billard; R E Worthington; J Gagnon; G Uzan
Journal:  J Biol Chem       Date:  1991-01-05       Impact factor: 5.157

Review 3.  A genetic model for colorectal tumorigenesis.

Authors:  E R Fearon; B Vogelstein
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

4.  Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan.

Authors:  M S Soloway; S W Hardeman; D Hickey; J Raymond; B Todd; S Soloway; M Moinuddin
Journal:  Cancer       Date:  1988-01-01       Impact factor: 6.860

5.  Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer.

Authors:  M Adachi; T Taki; Y Ieki; C L Huang; M Higashiyama; M Miyake
Journal:  Cancer Res       Date:  1996-04-15       Impact factor: 12.701

Review 6.  Proceedings: Diagnosis and staging of prostatic carcinoma.

Authors:  G R Prout
Journal:  Cancer       Date:  1973-11       Impact factor: 6.860

7.  TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins.

Authors:  R Oren; S Takahashi; C Doss; R Levy; S Levy
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

8.  A new superfamily of lymphoid and melanoma cell proteins with extensive homology to Schistosoma mansoni antigen Sm23.

Authors:  H W Gaugitsch; E Hofer; N E Huber; E Schnabl; T Baumruker
Journal:  Eur J Immunol       Date:  1991-02       Impact factor: 5.532

9.  C33 antigen recognized by monoclonal antibodies inhibitory to human T cell leukemia virus type 1-induced syncytium formation is a member of a new family of transmembrane proteins including CD9, CD37, CD53, and CD63.

Authors:  T Imai; K Fukudome; S Takagi; M Nagira; M Furuse; N Fukuhara; M Nishimura; Y Hinuma; O Yoshie
Journal:  J Immunol       Date:  1992-11-01       Impact factor: 5.422

10.  Prognostic factors in patients with advanced stage prostate cancer.

Authors:  L J Emrich; R L Priore; G P Murphy; M F Brady
Journal:  Cancer Res       Date:  1985-10       Impact factor: 12.701

View more
  16 in total

1.  Characterization of prostate cell types by CD cell surface molecules.

Authors:  Alvin Y Liu; Lawrence D True
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

2.  KAI1 gene is differently expressed in papillary and pancreatic cancer: influence on metastasis.

Authors:  Xiao-Zhong Guo; Helmut Friess; Xiao-Dong Shao; Min-Pei Liu; Yu-Ting Xia; Jian-Hua Xu; Markus W Buchler
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

3.  Frequent loss of KAI1 expression in squamous and lymphoid neoplasms. An immunohistochemical study of archival tissues.

Authors:  J Geradts; R Maynard; M J Birrer; D Hendricks; S L Abbondanzo; K M Fong; J C Barrett; D P Lombardi
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

4.  The expression of the KAI1 gene, a tumor metastasis suppressor, is directly activated by p53.

Authors:  T Mashimo; M Watabe; S Hirota; S Hosobe; K Miura; P J Tegtmeyer; C W Rinker-Shaeffer; K Watabe
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-15       Impact factor: 11.205

Review 5.  The Gordon Wilson Lecture. Natural history and treatment of early stage prostate cancer.

Authors:  P T Scardino
Journal:  Trans Am Clin Climatol Assoc       Date:  2000

6.  ANX7, a candidate tumor suppressor gene for prostate cancer.

Authors:  M Srivastava; L Bubendorf; V Srikantan; L Fossom; L Nolan; M Glasman; X Leighton; W Fehrle; S Pittaluga; M Raffeld; P Koivisto; N Willi; T C Gasser; J Kononen; G Sauter; O P Kallioniemi; S Srivastava; H B Pollard
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-03       Impact factor: 11.205

7.  Enhanced expression of SOS1 is detected in prostate cancer epithelial cells from African-American men.

Authors:  Olga A Timofeeva; Xueping Zhang; Habtom W Ressom; Rency S Varghese; Bhaskar V S Kallakury; Kan Wang; Youngmi Ji; Amrita Cheema; Mira Jung; Milton L Brown; Johng S Rhim; Anatoly Dritschilo
Journal:  Int J Oncol       Date:  2009-10       Impact factor: 5.650

8.  Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma.

Authors:  S Uchida; Y Shimada; G Watanabe; Z G Li; T Hong; M Miyake; M Imamura
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

9.  Lichen Secondary Metabolite, Physciosporin, Inhibits Lung Cancer Cell Motility.

Authors:  Yi Yang; So-Yeon Park; Thanh Thi Nguyen; Young Hyun Yu; Tru Van Nguyen; Eun Gene Sun; Jayalal Udeni; Min-Hye Jeong; Iris Pereira; Cheol Moon; Hyung-Ho Ha; Kyung Keun Kim; Jae-Seoun Hur; Hangun Kim
Journal:  PLoS One       Date:  2015-09-15       Impact factor: 3.240

10.  Clinicopathological significance of KAI1 expression and epithelial-mesenchymal transition in non-small cell lung cancer.

Authors:  Lei Zhou; Lan Yu; Shiwu Wu; Zhenzhong Feng; Wenqing Song; Xiaomeng Gong
Journal:  World J Surg Oncol       Date:  2015-08-01       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.